AGMB-101 is a Hepatocyte Growth Factor (HGF)-mimetic antibody that act through agonism of the MET receptor. The HGF/MET pathway is a critical modulator of the proliferation, survival, motility, and differentiation of cells and has a strong regenerative effect. Preclinical studies have clearly demonstrated its beneficial potential in a range of inflammatory and fibrotic disorders. The program has been developed using the validated SIMPLE Antibody™ platform from argenx. AGMB-101 is a full cMET receptor agonist.  As HGF’s regenerative capacity is tissue-agnostic, AGMB-101 can be positioned towards multiple inflammatory and fibrotic indications. AGMB-101 is currently in IND-enabling studies.